300+ investors in your industry, stage, and region Get
Any industry
Hospitality
Video Games
EdTech
Restaurants
Google
Construction
Photography
Cryptocurrency
Clean Energy
CleanTech
Big Data
Email
Artificial Intelligence
Social Impact
Energy
SaaS
Mobile
Consumer
Health Care
Enterprise Software
Local
Platforms
Travel
InsurTech
Oil and Gas
Retail
Film
Payments
Marketplace
Organic Food
Fitness
Machine Learning
Agriculture (AgTech)
Gaming
B2B
Social Network
Wellness
Education
Medical Device
Automotive
eSports
Sports
Legal
Biotechnology
Renewable Energy
Facebook
Blockchain
Software
Medical
Web3
Theatre
Recruiting
Crowdfunding
Infrastructure
Venture Capital
Beauty
Fashion
Social
Celebrity
LGBT
Climate
Cannabis
Wine and Spirits
Mobile Apps
Life Science
Food and Beverage
Publishing
Art
Music
Real Estate
Sporting Goods
FinTech
Finance
Digital Media
Manufacturing
Social Media
Financial Services
Franchise
Non Profit
Internet
Mobile Advertising
Android
Sustainability
Proptech
Hardware
Impact
Transportation
Biotech
Enterprise
Community
Media (Entertainment)
Any country
Afghanistan
Greece
United Kingdom
Thailand
United Arab Emirates
Andorra
Benin
Japan
South Korea
Singapore
Burkina Faso
LATAM
Brazil
Africa
Gibraltar
Egypt
Oceania
Taiwan
Zimbabwe
Tunisia
Sweden
Hong Kong
Nigeria
Togo
Croatia
Iran
Guinea
Kyrgyzstan
Haiti
Norway
Lesotho
Isle of Man
Liberia
Malawi
Nepal
Mexico
Madagascar
Russian Federation
Sudan
Pakistan
Tajikistan
Zambia
Romania
Puerto Rico
Oman
Poland
Guernsey
Cameroon
Armenia
Colombia
China
Costa Rica
Czech Republic
Kuwait
Marshall Islands
Luxembourg
Malta
Namibia
Mozambique
Mauritius
Nicaragua
Panama
Serbia
Uzbekistan
New Zealand
Australia
Jamaica
Sri Lanka
Switzerland
Guatemala
Kazakhstan
Cayman Islands
Venezuela
Uganda
Myanmar
Turkey
Uruguay
Morocco
Moldova
Seychelles
Botswana
Paraguay
South Africa
France
Denmark
Georgia
Ghana
Iraq
Portugal
Philippines
Sierra Leone
El Salvador
Senegal
India
Germany
Canada
Ireland
Saudi Arabia
Latvia
Kenya
Mali
Malaysia
Rwanda
Tanzania
United States
Indonesia
Middle East
Bermuda
Dominican Republic
Asia
Albania
Angola
Europe
Cyprus
Spain
Qatar
Argentina
Bangladesh
Barbados
Belgium
Austria
Ethiopia
Jordan
Azerbaijan
Ecuador
Bulgaria
Faroe Islands
Estonia
Bahrain
Bahamas
Jersey
Bolivia
Belize
Algeria
Belarus
Finland
Italy
Hungary
Israel
Grenada
Honduras
Iceland
Lithuania
Cambodia
Liechtenstein
Lebanon
Mongolia
Peru
San Marino
Slovenia
Ukraine
Chile
Vietnam
Angel Investors
VC Funds
All Investors
Access Full Database - Free Forever
Open database

Olivier Ossipoff

Chairman @ Xerys

Paris, France

Olivier Ossipoff is a venture - series unknown investor at Xerys in Paris focused on Health Care and Biotechnology. Olivier Ossipoff - Chairman @ Xerys

Total investments:
7
Last investment:
Lead investor:
100%

Last updated:

Industries Olivier Ossipoff invests in

Health CareBiotechnologyMedicalBiopharmaRecycling

Stages Olivier Ossipoff invests in

Venture - Series UnknownSeries B

Countries Olivier Ossipoff invests in

FranceUnited States

Contacts

TypeContactValidation
Work email
Personal email
Work phone
Personal phone
Socials

Sign up to unlock verified contacts

Unlock Contacts

Investment Focus

Industry

  • Health Care 2 (29%)
  • Biotechnology 2 (29%)
  • Medical 1 (14%)
  • Biopharma 1 (14%)
  • Recycling 1 (14%)
See all 11 industries →

Stage

  • Venture - Series Unknown 3 (43%)
  • Series B 1 (14%)

Country

  • France 3 (43%)
  • United States 1 (14%)

Investments

CompanyDescriptionRoundLinks
Advanced BioDesign, as an immunotechnology specialist, provides a tailored and high value solution to their research. This new company keeps his main research activity in Oncology, Infectious Diseases and in Neuroscience Fields. One of its major strengths is to follow its customers during the development of their own kits, from the feasibility tothe technology transfer. $15.6M / Venture - Series Unknown / Feb 02, 2023
Biolog-id is a designer-integrator which has specialized for the last thirty years in electronic identification and mobile data processing. It develops complete solutions for identification and traceability in life science.The mastering of the communication protocols, including those linked to the RFID (Radio Frequency Identification), and thecapacity to develop interface programs, allowing the company to answer to any specific demands is the solution in whichever environment is worked on. About seventy international patents protect the discoveries developed by Biolog-id. $25M / Venture - Series Unknown / May 05, 2022
Skytech provides innovative solutions and unique recovery services for plastics for the benefit of manufacturers. Skytech gives plastics a second life. It has developed TRIBLAST, an innovative and patented process for recycling polymers based on triboelectricity. It contributes to the development of the circular economy. $6.1M / Venture - Series Unknown / Jan 13, 2021
Advanced BioDesign, as an immunotechnology specialist, provides a tailored and high value solution to their research. This new company keeps his main research activity in Oncology, Infectious Diseases and in Neuroscience Fields. One of its major strengths is to follow its customers during the development of their own kits, from the feasibility tothe technology transfer. $9.8M / Venture - Series Unknown / Feb 25, 2020
Biolog-id is a designer-integrator which has specialized for the last thirty years in electronic identification and mobile data processing. It develops complete solutions for identification and traceability in life science.The mastering of the communication protocols, including those linked to the RFID (Radio Frequency Identification), and thecapacity to develop interface programs, allowing the company to answer to any specific demands is the solution in whichever environment is worked on. About seventy international patents protect the discoveries developed by Biolog-id. $33.2M / Venture - Series Unknown / Nov 19, 2019
AlzProtect is a biopharmaceutical company developing drug candidates from discovery to clinical trials for the treatment of neurodegenerative diseases including Alzheimer's disease (AD) and orphan tauopathies such as Progressive Supranuclear Palsy (PSP). $17.2M / Series B / Jan 22, 2018
Biolog-id is a designer-integrator which has specialized for the last thirty years in electronic identification and mobile data processing. It develops complete solutions for identification and traceability in life science.The mastering of the communication protocols, including those linked to the RFID (Radio Frequency Identification), and thecapacity to develop interface programs, allowing the company to answer to any specific demands is the solution in whichever environment is worked on. About seventy international patents protect the discoveries developed by Biolog-id. $7.7M / Venture - Series Unknown / Nov 08, 2016
Xerys

About Xerys

VC Fund · Paris, France

Xery is a portfolio management Company specializing in Venture Capital - Biotech, Medtech, Cleantech, Technology

Xerys Contacts

NameEmailPhoneSocials
Jacques Simonnet Chairman of the supervisory board
Olivier Ossipoff Chairman

Sign up to unlock verified contacts

Unlock Contacts

See all 2 contacts →

Access 48,091 investors

822 industries, 177 countries. Updated daily. Emails and phones included.

Browse database — It's Free!

Find investors for your startup

Search 48,091 investors by industry and country. Emails and phones included.

Any industry
Hospitality
Video Games
EdTech
Restaurants
Google
Construction
Photography
Cryptocurrency
Clean Energy
CleanTech
Big Data
Email
Artificial Intelligence
Social Impact
Energy
SaaS
Mobile
Consumer
Health Care
Enterprise Software
Local
Platforms
Travel
InsurTech
Oil and Gas
Retail
Film
Payments
Marketplace
Organic Food
Fitness
Machine Learning
Agriculture (AgTech)
Gaming
B2B
Social Network
Wellness
Education
Medical Device
Automotive
eSports
Sports
Legal
Biotechnology
Renewable Energy
Facebook
Blockchain
Software
Medical
Web3
Theatre
Recruiting
Crowdfunding
Infrastructure
Venture Capital
Beauty
Fashion
Social
Celebrity
LGBT
Climate
Cannabis
Wine and Spirits
Mobile Apps
Life Science
Food and Beverage
Publishing
Art
Music
Real Estate
Sporting Goods
FinTech
Finance
Digital Media
Manufacturing
Social Media
Financial Services
Franchise
Non Profit
Internet
Mobile Advertising
Android
Sustainability
Proptech
Hardware
Impact
Transportation
Biotech
Enterprise
Community
Media (Entertainment)
Any country
Afghanistan
Greece
United Kingdom
Thailand
United Arab Emirates
Andorra
Benin
Japan
South Korea
Singapore
Burkina Faso
LATAM
Brazil
Africa
Gibraltar
Egypt
Oceania
Taiwan
Zimbabwe
Tunisia
Sweden
Hong Kong
Nigeria
Togo
Croatia
Iran
Guinea
Kyrgyzstan
Haiti
Norway
Lesotho
Isle of Man
Liberia
Malawi
Nepal
Mexico
Madagascar
Russian Federation
Sudan
Pakistan
Tajikistan
Zambia
Romania
Puerto Rico
Oman
Poland
Guernsey
Cameroon
Armenia
Colombia
China
Costa Rica
Czech Republic
Kuwait
Marshall Islands
Luxembourg
Malta
Namibia
Mozambique
Mauritius
Nicaragua
Panama
Serbia
Uzbekistan
New Zealand
Australia
Jamaica
Sri Lanka
Switzerland
Guatemala
Kazakhstan
Cayman Islands
Venezuela
Uganda
Myanmar
Turkey
Uruguay
Morocco
Moldova
Seychelles
Botswana
Paraguay
South Africa
France
Denmark
Georgia
Ghana
Iraq
Portugal
Philippines
Sierra Leone
El Salvador
Senegal
India
Germany
Canada
Ireland
Saudi Arabia
Latvia
Kenya
Mali
Malaysia
Rwanda
Tanzania
United States
Indonesia
Middle East
Bermuda
Dominican Republic
Asia
Albania
Angola
Europe
Cyprus
Spain
Qatar
Argentina
Bangladesh
Barbados
Belgium
Austria
Ethiopia
Jordan
Azerbaijan
Ecuador
Bulgaria
Faroe Islands
Estonia
Bahrain
Bahamas
Jersey
Bolivia
Belize
Algeria
Belarus
Finland
Italy
Hungary
Israel
Grenada
Honduras
Iceland
Lithuania
Cambodia
Liechtenstein
Lebanon
Mongolia
Peru
San Marino
Slovenia
Ukraine
Chile
Vietnam
Angel Investors
VC Funds
All Investors

Similar Investors

Recommended lists

FAQ

What does Olivier Ossipoff invest in?

Olivier Ossipoff invests primarily in Health Care, Biotechnology and Medical startups, most often at Venture - Series Unknown and Series B stage. Most of the 7 investments tracked by Shizune back companies in France. The Investment Focus section breaks down every industry, stage and country in the portfolio.

How do I contact Olivier Ossipoff?

For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.

When did Olivier Ossipoff last invest?

The most recent investment recorded for Olivier Ossipoff closed in Feb 2023. Shizune tracks 7 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.

Is Shizune's investor data accurate?

Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Oct 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.

Contact your first 100 investors today

Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.

Find investors — It's Free!
Olivier Ossipoff Find email